Skip to main content
OpenTrials
Completed

NCT Number: NCT06236113

Low Dose Ketamine for Blunt Thoracic Trauma

The goal of this Randomized controlled double-blinded trial is to compare the addition of a ketamine infusion to placebo, when added to standard care in adult blunt trauma patients with multiple rib fractures. The main question it aims to answer are: • addition of low dose ketamine infusion (LDKI) decreases narcotic use • does LDKI impact pulmonary complications, readmission, or hospital length of stay Participants will receive usual standard of care with up to 48 hours of LDKI or placebo. If there is a comparison group: Researchers will compare infusion of a saline infusion to LDKI to see if LDKI decreases need for narcotic analgesics use.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

North Memorial Health Hospital

Robbinsdale, Minnesota, 55422, United States

About this study

Study Design: Randomized controlled double-blinded trial: Patients will then be randomized into one of two study groups. Both groups will receive a normal saline infusion for 48 hours of therapy. The treatment group will have ketamine added to their saline infusion via blinded pharmacy protocol to receive continuous infusion of ketamine at 0.1mg/kg/hour. The control group will receive only normal saline. Administration will occur via piggyback infusion in accordance with nursing policy.

Setting/Participants:

  • North Memorial Health Hospital: patients on 5-South - Trauma Neuro Intensive Care Unit (TNICU) and 6-West - Trauma Floor
  • 50 people will take part in this study. 25 study subjects will receive an infusion of ketamine and 25 will receive a saline infusion.
  • Patients 18 years of age or older with 3 or more rib fractures admitted to North Memorial Health Hospital will be considered for the study.

Study Interventions and Measures:

  • Ketamine low-dose infusion administered at 0.1 mg/kg/hr for 48 hours as an adjunct to standardized rib fracture management interventions as outlined in facility-approved Guidelines for Rib Fracture Management.
  • The primary study outcome will be amount of narcotic used over the 48-hour study period (expressed as morphine mg equivalents).
  • Secondary outcome measures will include: need for endotracheal intubation or non-invasive positive pressure ventilation, oxygen requirements, daily incentive spirometer values, daily forced vital capacity measurements, and subjective patient pain ratings.
  • Other outcomes measured will be Intensive Care Unit stay, total hospital length of stay, and adverse medication effects.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males or females 18 years of age or older
  • Diagnosis of 3 or more acute rib fractures related to blunt traumatic chest injury.
  • Able to undergo consent procedure and give valid consent, or availability of family member to provide consent for the study

Exclusion criteria

  • Age <18 years
  • Cognitively impaired
  • Pregnant or lactating females.
  • Glasgow Coma Score (GCS) of ≤ 14 at time of admission
  • Evidence of increased intraocular pressure
  • Presence of acute coronary syndrome
  • Diagnosed moderate to severe traumatic brain injury
  • Evidence of uncontrolled intracranial hypertension
  • History of seizures or stroke
  • History of severe psychiatric disorders
  • Allergy to ketamine
  • Currently being treated, prior to admission, with opiate agonist/antagonist therapy
  • Presence of poorly controlled hypertension, cardiac arrhythmias, and/or tachycardia on admission
  • Subjects who, in the opinion of the Investigator, may be inappropriate for study participation.

Treatment and study plan

Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution

Drug

administered at rate of 0.1 mg/kg/hr

Other names: Low Dose Ketamine Infusion, Ketamine Drip

Primary outcomes

  1. Milligrams of Morphine Equivalents (MME) Administered

    Time frame: Outcome was evaluated up to a total of 96 hours (from time zero to 48 hours of infusion and up to 48 hrs after infusion stopped.

    Standardized method of reporting narcotic analgesic administration by converting opioid narcotics to the equivalent dosage of morphine that would yield same result.

Secondary outcomes

  1. Pulmonary Complications

    Time frame: Up to 30 days after intervention (administration of study drug)

    Number of participants that develop pneumonia, require intubation, or non-invasive positive pressure ventilation

  2. ICU Admission or Hospital Readmission

    Time frame: Up to 30 days after intervention (administration of study drug)

    Number of participants that requirie transfer to ICU (e.g., respiratory difficulty, tachycardia, hypotension, altered mental status) or that readmission to hospital after discharge for any reason.

Sponsors and collaborators

Lead sponsor

North Memorial Health Care

Other

Registry information

Official study title

Low Dose Ketamine for Blunt Thoracic Trauma: A Prospective Randomized Trial

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Feb 1, 2024
Registry last updated
May 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.